Epstein-Barr Virus Market Size in the 7MM is estimated to Increase by 2032 | ModernaTX Inc., Henogen, Atara Biotherapeutics, Viracta Therapeutics Inc., Eutilex, Epiphany Biosciences, Hoffmann-La Roche, and others.

{Delhi, India}, To strategically aid Epstein-Barr Virus Companies in developing drugs for Epstein-Barr Virus, DelveInsight launched a report titled “Epstein-Barr Virus Market Insight Epidemiology and Market Forecast 2032”. This comprehensive report delves into epidemiology-based market analysis, providing a roadmap for success in the dynamic landscape of the Epstein-Barr Virus Market.

Download a free sample report on “Epstein-Barr Virus Market”

Key Takeaways from the Epstein-Barr Virus Market Research Report

• The Epstein-Barr Virus Market Size in the seven major markets was approximately USD 1.5 Billion in 2021.
• The launch of novel therapies would significantly contribute toward an increase in the Epstein-Barr Virus Market size in the 7MM.
• The Epstein–Barr Virus (EBV) Market Dynamics are anticipated to change during the forecast period (2023–2032) owing to the launch of novel therapies in clinical development and the development of basic research, clinical medicine, and new ideas related to the pathogenesis and clinical aspects of EBV-associated diseases.
• The leading Epstein-Barr Virus Companies working in the market include ModernaTX Inc., Henogen, Atara Biotherapeutics, Viracta Therapeutics Inc., Eutilex, Epiphany Biosciences, Hoffmann-La Roche, China Immunotech (Beijing) Biotechnology Co., Ltd., Tessa Therapeutics, Bristol-Myers Squibb, AlloVir, Marengo Therapeutics Inc., GlaxoSmithKline, Acerta Pharma BV, Merck Sharp & Dohme LLC, Pharmacyclics LLC, Janssen Research & Development LLC, Parexel, Gilead Sciences, Cothera Bioscience Inc., Immunitas Therapeutics, Schrödinger Inc., ADC Therapeutics S.A., Seagen Inc., Morphotek, Novartis Pharmaceuticals, Millennium Pharmaceuticals Inc., Takeda, Jazz Pharmaceuticals, AstraZeneca, and others.
• Promising Epstein-Barr Virus Pipeline Therapies in the various stages of development include Rituximab, Multivirus Specific T cells, lenalidomide, CC-486, Pegfilgrastim, AR-42, Cyclophosphamide, ATA188, Obinutuzumab, Venetoclax, Clofarabine, AZD3965, CPX-351, Acyclovir, and others.

Epstein-Barr Virus Country-based Treatment Analysis

The Epstein-Barr Virus Treatment Market Report provides treatment regimens across the 7MM. It will help companies to analyze the practices followed across 7MM, the patient journey, and advances in Epstein-Barr Virus therapies that have potential treatment paradigms and improve patient outcomes.

Epstein-Barr Virus, also known as human herpesvirus 4 (HHV-4), is a member of the herpes virus family. It is one of the most common human viruses. Epstein-Barr Virus is found worldwide. Most people get infected with Epstein-Barr Virus at some point in their lives; Epstein-Barr Virus spreads most commonly through bodily fluids, primarily saliva. Epstein-Barr Virus can cause infectious mononucleosis (IM) and has been associated with certain cancers, including Burkitt lymphoma, immunoblastic lymphoma, nasopharyngeal cancer, and stomach (gastric) cancer.

Download the report to understand which factors are driving Epstein-Barr Virus Epidemiology trends @ Epstein-Barr Virus Epidemiology Forecast

Epstein-Barr Virus Epidemiology

The report proffers historical and forecasted epidemiology insights that help to understand the target Epstein-Barr Virus patient population. The analysis is from 2019-2032, providing insights into how the patient trends are going to shape Epstein-Barr Virus market dynamics. Further, the epidemiology is segmented to provide an in-depth analysis of patient pools allowing companies to understand their target patient pools.

Epstein-Barr Virus Epidemiology Segmentation in the 7MM

• Total Epstein-Barr Virus Diagnosed Incident Cases
• Epstein-Barr Virus Incident Cases
• Total Epstein-Barr Virus Incident Cases

“As per DelveInsight’s assessments, the total incident cases of EBV+ Cancers and PTLD calculated by adding the cases in individual countries in 2021 were nearly 48,000 in the 7MM, out of which the highest number of cases were seen in the US”

Epstein-Barr Virus Companies and Therapies

• Celgene: Lenalidomide
• Millennium Pharmaceuticals Inc.: Doxorubicin Hydrochloride
• Atara Biotherapeutics: ATA188
• Genentech Inc.: Obinutuzumab
• Genzyme: Cyclophosphamide

To learn more about Epstein-Barr Virus Companies working in the treatment market, visit @ Epstein-Barr Virus Clinical Trials and Therapeutic Assessment

Epstein-Barr Virus Drugs Uptake

Nanatinostat (VRx-3996) is an orally available histone deacetylase (HDAC) inhibitor developed by Viracta. Nanatinostat is selective for specific isoforms of Class I HDACs, which is key to inducing viral genes that are epigenetically silenced in EBV-associated malignancies.

Tabelecleucel (tab-cel) is an off-the-shelf, allogeneic T-cell immunotherapy. Tab-cel is under investigation for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) and is in earlier stage development for other EBV-associated diseases. Tab-cel, Atara's most clinically advanced T-cell immunotherapy in development, is currently being investigated in the Phase III registration- enabling ALLELE study to assess efficacy and safety for the treatment of EBV+ PTLD in SOT after failure of rituximab or rituximab and chemotherapy, and in HCT after failure of rituximab (NCT03394365, ALLELE study).

AlloVir’s lead product, posoleucel, is in late-stage clinical development as an allogeneic, off-the-shelf, multi-virus-specific T-cell therapy targeting six viral pathogens in immunocompromised individuals: adenovirus (AdV), BK virus (BKV), CMV, EBV, human herpesvirus-6 (HHV-6) and JC virus (JCV).

Epstein-Barr Virus Treatment Landscape

With improved laboratory tests for EBV, a timelier and more accurate diagnosis could aid in better prognosis and effective treatment. For histopathological lesions, the in situ hybridization (ISH) of EBV-encoded RNA (EBER) in biopsy tissues remains the gold standard for detecting EBV. Methods such as the heterophile antibody test, immunofluorescence assays, enzyme immunoassays, Western blot, and polymerase chain reaction (PCR) are also employed in detecting EBV in different types of samples. However, detecting EBV viral load using PCR is gaining more prominence in diagnosing EBV-associated diseases.

Epstein-Barr Virus Emerging Therapies and Companies

• Nanatinostat in Combination With valganciclovir (Nana-val): Viracta Therapeutics
• Tabelecleucel (tab-cel): Atara Biotherapeutics
• Posoleucel (viralym-M; ALVR-105): AlloVir

Discover more about therapies set to grab major Epstein-Barr Virus Market Share @ Epstein-Barr Virus Treatment Market

Scope of the Epstein-Barr Virus Market Research Report

• Coverage- 7MM
• Study Period- 2019-2032
• Forecast Period- 2023-2032
• Epstein-Barr Virus Companies- ModernaTX Inc., Henogen, Atara Biotherapeutics, Viracta Therapeutics Inc., Eutilex, Epiphany Biosciences, Hoffmann-La Roche, China Immunotech (Beijing) Biotechnology Co., Ltd., Tessa Therapeutics, Bristol-Myers Squibb, AlloVir, Marengo Therapeutics Inc., GlaxoSmithKline, Acerta Pharma BV, Merck Sharp & Dohme LLC, Pharmacyclics LLC, Janssen Research & Development LLC, Parexel, Gilead Sciences, Cothera Bioscience Inc., Immunitas Therapeutics, Schrödinger Inc., ADC Therapeutics S.A., Seagen Inc., Morphotek, Novartis Pharmaceuticals, Millennium Pharmaceuticals Inc., Takeda, Jazz Pharmaceuticals, AstraZeneca, and others.
• Epstein-Barr Virus Pipeline Therapies- Rituximab, Multivirus Specific T cells, lenalidomide, CC-486, Pegfilgrastim, AR-42, Cyclophosphamide, ATA188, Obinutuzumab, Venetoclax, Clofarabine, AZD3965, CPX-351, Acyclovir, and others.
• Epstein-Barr Virus Market Dynamics: Epstein-Barr Virus Market Drivers and Barriers

Note:-

DelveInsight's report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the Epstein-Barr Virus Market Landscape.

Gain Competitive Edge in the Indication Market: Understand the current landscape of the Epstein-Barr Virus Market, including the competitive environment, key companies developing drugs for Epstein-Barr Virus, and their strategies. By analyzing Epstein-Barr Virus Market Dynamics, treatment approaches, and emerging therapies, stakeholders can identify opportunities to position themselves effectively, gaining a competitive edge over others.

Identify Market Gaps and indication market opportunities: Analyzing epidemiological trends, country-wise patient journeys, and existing treatment practices can help in identifying gaps and opportunities within the Epstein-Barr Virus Market. This involves recognizing areas where current treatments may be insufficient or where there is an unmet need. The report is curated by taking account of various KOLs dealing with the Epstein-Barr Virus. Identifying these gaps allows stakeholders to explore new therapeutic avenues, potentially leading to the development of novel treatments that address specific market needs and price their emerging products strategically to gain a competitive edge.

Strategic decision-making: Armed with insights from epidemiological and market forecasts, stakeholders can make informed and strategic decisions. This may involve deciding on research and development investments, portfolio expansion, pricing-reimbursement strategies, partnerships, or other strategic moves. Understanding the Epstein-Barr Virus market dynamics enables stakeholders to align their goals with the prevailing trends and future projections.

Plan Roadmap to Success: Through this report, the leading Epstein-Barr Virus companies can set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap ensures that stakeholders navigate the complexities of the Epstein-Barr Virus Market with clarity and purpose.

Related Articles-

Changing Landscape of EBV-associated Diseases Treatment: Is T-cell Immunotherapy the Answer?

Epstein Barr Virus Market Infographics

Related Reports

Epstein Barr virus Epidemiology Forecast 2032

DelveInsight's Epstein Barr virus (EBV) - Epidemiology Forecast 2032 report delivers an in-depth understanding of the disease, and historical, and forecasted epidemiology.

Epstein Barr virus Pipeline Insight, 2023

Epstein Barr virus (EBV) Pipeline Insights, 2023 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the EPV market.

Explore Our Success Story of Building an Interactive Competitive Intelligence Dashboard for HR+ HER2- Breast Cancer Market Landscape. Download our Oncology Competitive Intelligence Case study! 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Yash Bhardwaj

Team Lead- Marketing

Email: info@delveinsight.com

Website: https://www.delveinsight.com/